

Art Unit: 1600

CLAIMS PTO

1/04/03

GJT

CLAIMS 1-315 ARE CANCELLED

CLAIM 316 IS AMENDED

316. (Amended) A pharmaceutical composition comprising a carrier and an isolated keratinocyte growth factor (KGF) polypeptide prepared by expressing in a host cell a DNA encoding a polypeptide having a sequence comprising amino acids 32 - 194 of Figure 7.

317. The pharmaceutical composition of claim 316, wherein said DNA encodes a Met at the amino terminus.

318. The pharmaceutical composition of claim 316, wherein said host cell is selected from the group consisting of a bacterial cell, a fungal cell, a mammalian cell and an insect cell.

319. The pharmaceutical composition of claim 318, wherein said cell is a bacterial cell.

320. The pharmaceutical composition of claim 318, wherein said cell is a mammalian cell.

CLAIM 321 IS AMENDED

321. (Amended) A pharmaceutical composition comprising a carrier and an isolated keratinocyte growth factor (KGF) polypeptide, wherein said polypeptide comprises amino acids 32 to 194 of Figure 7 or comprises a segment of said polypeptide, wherein said polypeptide and segment thereof has mitogenic activity on BALB/MK cells.

Art Unit: 1600

322. The pharmaceutical composition of claim 321, wherein said polypeptide or segment thereof comprises Met at the amino terminus.

323. The pharmaceutical composition of claim 321, wherein five nanomolar concentration of said polypeptide or segment thereof elicits less than one-fold stimulation over background in NIH/3T3 cells.

324. The pharmaceutical composition of claim 321, wherein said polypeptide or segment thereof is capable of stimulating DNA synthesis in quiescent BALB/MK epidermal keratinocytes at a concentration of 0.1 nM.

325. The pharmaceutical composition of claim 321, wherein an amount of said polypeptide that stimulates maximal thymidine incorporation in BALB/MK keratinocyte cells, stimulates less than one-fold stimulation over background in NIH/3T3 fibroblasts.

326. The pharmaceutical composition of claim 321, wherein an amount of said polypeptide or segment thereof that stimulates maximal thymidine incorporation in BALB/MK keratinocyte cells, stimulates less than 1/50th of the maximal thymidine incorporation in NIH/3T3 cells stimulated by aFGF or bFGF.

327. The pharmaceutical composition of claim 321, wherein an amount of said polypeptide or segment thereof that stimulates maximal thymidine incorporation in BALB/MK keratinocyte cells, stimulates less than 1/10th of the maximal thymidine incorporation in NIH/3T3 fibroblasts stimulated by EGF or TGF-alpha.

328. The pharmaceutical composition of claim 321, wherein the maximal thymidine incorporation in BALB/MK keratinocytes stimulated by said polypeptide or segment thereof obtained within the concentration range of 0.1 to 3 nanomolar is at least twice that obtained with bFGF within the same concentration range.

CLAIM 329 IS AMENDED

329. (Amended) A pharmaceutical composition comprising a carrier and an isolated keratinocyte growth factor (KGF) polypeptide, wherein said polypeptide comprises the amino acids 32-194 of Figure 7 or comprises a segment of said polypeptide which is that part of the amino acid sequence of Figure 7 that remains after the amino acid sequence of Figure 7 is truncated from an N terminus to C terminus direction, within the region of amino acids 32-78.

330. The pharmaceutical composition of claim 329, wherein said polypeptide or segment thereof comprises Met at the amino terminus.

331. The pharmaceutical composition of claim 329, wherein said polypeptide or segment thereof, which has mitogenic activity on BALB/MK keratinocyte cells.

332. The pharmaceutical composition of claim 329, wherein said polypeptide or segment thereof has mitogenic activity on epithelial cells.

CLAIM 333 IS AMENDED

333. (Amended) A pharmaceutical composition comprising a carrier and an isolated keratinocyte growth factor (KGF) polypeptide, wherein said polypeptide comprises amino acids 32-194 of Figure 7 or comprises a segment of said polypeptide which is that part of the amino acid sequence of Figure 7 that remains after the amino acid sequence of Figure 7 is truncated from the C terminus toward the N terminus, within the region of amino acids 194 to 189.

334. The pharmaceutical composition of claim 333, wherein said polypeptide or segment thereof comprises Met at the amino terminus.

CLAIM 335 IS AMENDED

Art Unit: 1600

335. (Amended) The pharmaceutical composition of claim 333, wherein said polypeptide or segment thereof has mitogenic activity on BALB/MK keratinocyte cells

336. The pharmaceutical composition of claim 333, wherein said polypeptide or segment thereof has mitogenic activity on epithelial cells.

CLAIM 337 IS AMENDED

337. (Amended) A pharmaceutical composition comprising a carrier and an isolated keratinocyte growth factor (KGF) polypeptide, wherein said polypeptide comprises amino acids 32-194 of Figure 7 or comprises a segment of said polypeptide which is that part of the amino acid sequence of Figure 7 that remains after the amino acid sequence of Figure 7 is truncated from an N terminus to C terminus direction, within the region of amino acids 32-78 and is truncated from the C terminus toward the N terminus, within the region of amino acids 194 to 189.

338. The pharmaceutical composition of claim 337, wherein said polypeptide or segment thereof comprises Met at the amino terminus.

339. The pharmaceutical composition of claim 337, wherein said polypeptide or segment thereof has mitogenic activity on BALB/MK keratinocyte cells.

340. The pharmaceutical composition of claim 337, wherein said polypeptide or segment thereof has mitogenic activity on epithelial cells.

CLAIM 341 IS AMENDED

341. (Amended) A pharmaceutical composition comprising a carrier and an isolated keratinocyte growth factor (KGF) polypeptide, wherein said polypeptide comprises amino acids 32-194 of Figure 7.

342. The pharmaceutical composition of claim 341, wherein said polypeptide comprises Met at the amino terminus.

CLAIM 343 IS AMENDED

343. (Amended) A pharmaceutical composition comprising a carrier and an isolated keratinocyte growth factor (KGF) polypeptide prepared by expressing in a host cell a DNA encoding an amino acid sequence comprising amino acids 32-194 of Figure 7 or encoding an amino acid sequence which is a segment of amino acids 32-194 of Figure 7, wherein the segment is that part of the amino acid sequence of Figure 7 that remains after the amino acid sequence of Figure 7 is truncated from an N terminus to C terminus direction, within the region of amino acids 32-78.

344. The pharmaceutical composition of claim 343, wherein said DNA encodes Met at the amino terminus.

345. The pharmaceutical composition of claim 343, wherein said polypeptide has mitogenic activity on BALB/MK keratinocyte cells.

346. The pharmaceutical composition of claim 343, wherein said polypeptide has mitogenic activity on epithelial cells.

CLAIM 347 IS AMENDED

347. (Amended) A pharmaceutical composition comprising a carrier and an isolated keratinocyte growth factor (KGF) polypeptide, wherein said polypeptide comprises amino acids 32 to 194 of Figure 7 or comprises a segment of said polypeptide, and wherein said polypeptide and segment thereof has mitogenic activity on epithelial cells.

Art Unit: 1600

348. The pharmaceutical composition of claim 347, wherein said polypeptide or segment thereof comprises Met at the amino terminus.

349. The pharmaceutical composition of claim 347, wherein said polypeptide is a segment of the polypeptide of Figure 7.

350. The pharmaceutical composition of claim 347, wherein five nanomolar concentration of said polypeptide or segment thereof elicits less than one-fold stimulation over background in NIH/3T3 cells.

351. The pharmaceutical composition of claim 347, wherein said polypeptide is capable of stimulating DNA synthesis in quiescent BALB/MK epidermal keratinocytes at a concentration of 0.1 nM.

352. The pharmaceutical composition of claim 347, wherein an amount of said polypeptide or segment thereof that stimulates maximal thymidine incorporation in BALB/MK keratinocyte cells, stimulates less than one-fold stimulation over background in NIH/3T3 fibroblasts.

CLAIMS 353 AND 354 ARE AMENDED

353. (Amended) The pharmaceutical composition of claim 347, wherein an amount of said polypeptide or segment thereof, that stimulates maximal thymidine incorporation in BALB/MK keratinocyte cells, stimulates less than 1/50'th of the maximal thymidine incorporation in NIH/3T3 cells stimulated by aFGF or bFGF.

354. (Amended) The pharmaceutical composition of claim 347, wherein an amount of said polypeptide or segment thereof that stimulates maximal thymidine incorporation in BALB/MK keratinocyte cells, stimulates less than 1/10th of the maximal thymidine incorporation in NIH/3T3 fibroblasts stimulated by EGF or TGF-alpha.

355. The pharmaceutical composition of claim 347, wherein the maximal thymidine incorporation in BALB/MK keratinocytes stimulated by said polypeptide or segment thereof obtained within the concentration range of 0.1 to 3 nanomolar is at least twice that obtained with bFGF within the same concentration range.

CLAIMS 356 AND 357 ARE AMENDED

356. (Amended) A pharmaceutical composition comprising a carrier and an isolated keratinocyte growth factor (KGF) polypeptide comprising a segment of amino acids 32-94 of Figure 7, wherein said polypeptide and segment thereof has mitogenic activity on epithelial cells and wherein said polypeptide is unglycosylated.

357. (Amended) A pharmaceutical composition comprising a carrier and an isolated keratinocyte growth factor (KGF) polypeptide comprising a segment of amino acids 32-194 of Figure 7, wherein the segment is that part of the amino acid sequence of Figure 7 that remains after the amino acid sequence of Figure 7 is truncated from an N terminus to C terminus

direction, within the region of amino acids 32-78, and wherein said polypeptide is unglycosylated.

358. The pharmaceutical composition of any of claims 316 to 355, wherein said polypeptide or segment thereof is unglycosylated.

359. The pharmaceutical composition of any of claims 316 to 355, wherein said polypeptide or segment thereof is glycosylated.--

Application/Control Number: 08/477,983

Page 9

Art Unit: 1600